anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The PA group will receive a 6-week home-based self-defence training programme consisting of 120 min video training (including daily practice time) per week. Self-report questionnaires will be collected at baseline, immediate post-intervention, and 4-week follow up assessments.
* Do not shake. Do not use Epogen that has been shaken or frozen.  

  * Protect vials from light.  

  * Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Do not use any vials exhibiting particulate matter or discoloration.  

  * Discard unused portions of Epogen in preservative-free vials. Do not re-enter preservative-free vials.  

  * Store unused portions of Epogen in multiple-dose vials at 36°F to 46°F (2°C to 8°C). Discard 21 days after initial entry.  

  * Do not dilute. Do not mix with other drug solutions except for admixing as described below:



Preservative-free Epogen from single-dose vials may be admixed in a syringe with bacteriostatic 0.9% sodium chloride injection, USP, with benzyl alcohol 0.9% (bacteriostatic saline) in a 1:1 ratio using aseptic technique at the time of administration. Do not mix Epogen with bacteriostatic saline when administering to pregnant women, lactating women, neonates, and infants [see Use in Specific Populations (8.1, 8.2, 8.4)].
PROBLEM TO BE SOLVED: To obtain a medicinal composition without damaging its efficacy by trapping a foul smell caused by a compound containing sulfur. SOLUTION: A medicinal composition containing an active ingredient generating a foul smell caused by a compound containing sulfur, is blended with a corrin-based compound for controlling the foul smell. As the corrin-based compound which is a compound having a corrin nucleus (a corrin ring), cyanocobalamine, hydroxocobalamine and methylcobalamine are cited. Based on 1mol compound containing sulfur (e.g.; hydrogen sulfide and methylmercaptane), 1-2000mol corrinoid-based compound is blended. Based on 1wt.% medicinal active ingredient, 10-0.0001wt.% corrinoid-based compound is blended. The composition can be prepared as an orally ingesting preparation and a perparation for external use, and their feelings in taking are improved.
Participants in the open results arm will be provided with Gluten Detective home testing kits (immunochromatographic lateral flow tests) at week 8 of the study for immediate qualitative (yes/no) feedback about the presence of biomarkers of gluten in their stool and/or urine. During the period from week 8 to week 30, participants will be contacted a total of 6 times at random intervals to collect and test urine samples and complete a questionnaire.Additionally, participants will be given 4 stool test kits, with instructions that they may use these at times of their choosing and will report results and reasons for test use, if any. During this time participants will also keep a diary of suspected gluten exposures. All samples collected will be returned during the week 30 study visit.
Arterial stiffness (AS) and chronic kidney disease (CKD) are common in the older population. AS results in increased pulsatile pressure, elevated pulse pressure (PP), and is linked to hypertension. PP is a surrogate for AS. The kidney has low vascular resistance mechanisms, presumably making it vulnerable to the increased pulsatile pressure and hypertension associated with AS. The aims of this study were to investigate the impact of PP elevation on incident CKD (glomerular filtration rate < 60 ml/min/1.73 m2) and all-cause mortality. The data was collected from the general population cohort study "Good Aging in Skåne". Cox proportional hazard regression models adjusted for age, sex, diabetes, and smoking habits were used to investigate the impact of three levels of PP elevation on incident CKD (n = 2693) and all-cause mortality (n = 5253). For PP < 60 mmHg, the median survival time was 18.7 years (event incident CKD) and first quartile survival time (event all-cause mortality) 15.4 years. Elevated PP ≥ 80 mmHg was associated with incident CKD (hazard ratio 1.59, CI 1.28-1.97), but not all-cause mortality. Our results suggest that a finding of PP ≥ 80 mmHg in older age should raise concern of kidney function.
Participants received a single SC injection of placebo Corifollitropin Alfa on day 2 or 3 of the menstrual cycle (Stimulation Day 1); 7 daily SC injections with 200 IU recFSH from Stimulation Days 1 to 7; followed by daily SC injections with 200 IU recFSH up to the day of hCG. Daily SC injections of Ganirelix were given from Stimulation Day 5 to the day of hCG; at which time a single dose of hCG was administered when 3 follicles \>= 17 mm. On the day of OPU daily doses of progesterone were started and continued for up to 6 weeks or menses.
Fucoxanthin, a dietary carotenoid, is predominantly found in edible brown algae and is commonly consumed worldwide. Fucoxanthin has been shown to possess beneficial health activities such as antidiabetic, anti-inflammatory, antimutagenic, and antiobesity; however, the effects of fucoxanthin on VEGF-mediated angiogenesis and its possible binding with VEGF are unknown. Here, different lines of evidence supported the suppressive roles of fucoxanthin in VEGF-mediated angiogenesis. In human umbilical vein endothelial cells, fucoxanthin remarkedly suppressed VEGF-mediated cell proliferative, migration, and invasive abilities, as well as tube formation, without cytotoxicity. In addition, fucoxanthin inhibited the subintestinal vessel formation of zebrafish in vivo. In signaling cascades, fucoxanthin was proposed to interact with VEGF, thus attenuating VEGF's functions in activating the VEGF receptor and its related downstream signaling, i.e., phosphorylations of MEK and Erk. Fucoxanthin also significantly blocked VEGF-triggered ROS formation. Furthermore, the outcomes of applying fucoxanthin in cancer cells were identified, which included (i) inhibiting VEGF-mediated cell proliferation and migration and (ii) inhibiting NF-κB translocation via limiting MMP2 expression. These lines of investigations supported the antiangiogenic roles of fucoxanthin, as well as reviewing its signaling mechanisms, in blocking the VEGF-triggered responses. The results would benefit the potential development of fucoxanthin for the prevention and treatment of angiogenesis-related diseases.
Naldebain, a long-acting analgesic injection, obtained a license from the Taiwan Food and Drug Administration (TFDA) of the Ministry of Health and Welfare on March 6, 2017 to approve a sustained-release long-acting analgesic on the market in Taiwan. At present, it is the only analgesic injection that has an efficacy of up to seven days. The currently approved drug indication is to relieve moderate and severe acute pain after surgery. Pharmacological mechanisms and experiments show that its analgesic effect is equivalent to morphine, but its side effects are much lower than morphine. Because of its special pharmacological mechanism, it has extremely high potential to improve patients undergoing knee replacement surgery. Therefore, this study hopes to use a rigorous double-blind randomized controlled experiment to understand whether the new sustained-release analgesic Naldebain can achieve effective pain relief for patients undergoing knee replacement surgery, and to evaluate the patient's functional recovery status .
FIELD: medicine, endocrinology, hormones. SUBSTANCE: invention relates to the concentrated aqueous preparative forms of insulin with high physical and chemical stability. Method relates to the development of the insulin preparative form wherein the concentration of chloride ion is below 50 mM and the concentration of other ions, such as phosphate, is minimized. An aqueous preparative form of insulin comprises from 3 to 20 mM of human insulin or its analogue or its derivative, less 50 mM of chloride, less 10 mM of any anions different than chloride and acetate, from 2 to 5 Zn 2+  ions per 6 insulin molecules and at least 3 phenol molecules per 6 insulin molecules. The proposed preparative insulin forms can be used for delivery by way of lung. EFFECT: valuable properties of insulin forms, expanded assortment of insulin preparations. 19 cl, 3 tbl
INTRODUCTION: There are multiple ongoing outbreaks of carbapenem resistant Acinetobacter baumannii (CRAb) infection in Fiji's hospitals. CRAb is able to colonize and persist on various hospital surfaces for extended periods. We conducted a study to understand the extent of hospital environmental contamination and phylogenetic links with clinical isolates.
METHODS: Swabs were collected from high-touch surfaces at Colonial War Memorial Hospital (CWMH) September 2021 and December 2022; Lautoka Hospital (LTKH) August 2022; and Labasa Hospital (LBSH) November 2022. All bacterial isolates were identified, and antimicrobial susceptibility testing (AST) performed; isolates resistant to carbapenems and producing a carbapenemase underwent whole genome sequencing. Comparison was made to clinical isolates obtained from CWMH in 2016-2017 and 2019-2021 and from LTKH and LBSH from 2020-2021.
RESULTS: From the 180 environmental samples collected, ten (5.6%) CRAb were isolated; no other carbapenem-resistant gram-negative organisms were isolated. Seven (70%) of the CRAb were isolated from CWMH and three (30%) from LTKH; no CRAb were isolated from LBSH. Of the seven CWMH CRAb, two were sequence type 2 (ST2), three ST25, and two ST499. All LTKH isolates were ST499. The two environmental CRAb ST2 isolates were closely genetically linked to isolates obtained from patients in CWMH, LTKH, and LBSH 2020-2021. Similarly, the three environmental CRAb ST25 isolates were closely genetically linked to isolates obtained from patients admitted to CWMH in 2019-2021 and LBSH in 2020. The environmental CRAb ST499 isolates represented two distinct clones, with clone 1 comprising two genetically identical isolates from CWMH and clone 2 the three isolates from LTKH. Although no genetic linkages were observed when comparing environmental ST499 isolates to those from CWMH patients in 2020-2021, both clone 1 isolates were genetically identical to an isolate obtained from a patient admitted during the sampling period.
CONCLUSION: Our study highlights the contamination of high-touch surfaces within Fiji hospitals with CRAb, suggesting that these may serve as important sources for CRAb. Phylogenetic linkages to CRAb isolated from patients since 2019 underscores the persistence of this resistant pathogen in hospital settings and the ongoing risk for hospital-acquired infections.
The invention discloses a constructing method of subtype HCN4 restructured virus carrier of pacing channel gene, comprising HCN4 restructured virus carrier built by shuttling plasmid with HCN4 gene and virus system together. The shuttling plasmid is pCDH1-GFP-HCN4, and the virus is slow virus. The invention builds the HCN4 restructured virus carrier by the shuttling plasmid pCDH1-GFP-HCN4 with HCN4 gene and the slow virus together and the slow virus can infect not only the cleavage cell, but also the non-cleavage cell. The genome of the virus can be integrated in the host genome, can express the foreign gene long and steadily and also has an advantage of low immunogenicity. The genome of the virus is possible to be the best carrier for treating the gene. The invention can possibly lay a base for cell treatment and gene treatment of slow arrhythmia.
The investigators include patients aged 18-80 years with acute (less than 1-month) low back pain with or without radicular signs, who do not have severe diseases (abscess, tumor, etc) in the background, already had CT or MRI scan during routine workup, and who have given written consent to participate in the study. Exclusion criteria are pregnancy, hypersensitivity to tolperisone in the history, severe liver or kidney disease, other severe diseases (abscess, tumor, etc) in the background of pain. The patients will be given 3 times daily 150 mg tolperisone or placebo in addition to standard therapy in a randomized double-blind design. Treatment will last for 14 days and a final follow-up is performed at 21 days. Clinical condition and biomarkers will be tested before treatment and at 14 days. Patients fill in a diary on a daily basis.
Systemic autoimmune disease contributes up to ~22% of cases of pericarditis with known etiology. Systemic lupus erythematosus (SLE) is a multisystem disease with a variety of clinical presentations and manifestations. Since the underlying mechanism for pericardial involvement differs with each systemic disease, this leads to poor understanding of its management. However, it is rare for acute pericarditis to be the leading symptom at the time of diagnosis of SLE, occurring in up to 1% of patients. This is a case report of a 21-year-old female who presented with breathlessness and pedal edema, who was previously misdiagnosed with tubercular pericarditis and was started on antitubercular treatment (ATT). Now she is diagnosed with autoimmune pericarditis with SLEoverlap syndrome. Pericarditis, being the most common cardiac manifestation of SLE, has an incidence ranging between 11 and 54%. Knowledge of such association is necessary to avoid misdiagnosis.
The solitary pulmonary nodule (SPN) is a common finding in chest radiography. Pulmonary nodules larger than 1cm indicative of malignancy or with indeterminate finding according to morphology criteria have to be defined by invasive methods such as biopsy or surgical excision, and benign pathology makes up 20-50% of those resected pulmonary lesions. The lesions not receiving surgical intervention often need imaging follow-up on a regular basis for a long period of time to monitor the stability of the finding.

There are many reports regarding the MRI perfusion analysis of neoplasms from many organs, including bone marrow, liver, breast, cervix, and they stressed not only on comparison between benignity and malignancy, but also on monitoring the treatment outcomes after neoadjuvant chemotherapy, radiation therapy or anti-angiogenic agent therapy \[7-15\]. Dynamic contrast-enhanced MRI (DCE MRI) is not a standard examination for SPN, but there have been some data regarding the differentiation between malignant and benign SPN using DCE MRI, with MRI offering higher specificity compared to dynamic CT scan \[6, 7, 16\]. It was also reported that DCE MRI could delineate kinetic and morphologic differences in tumor angiogenesis and perfusion characteristics between malignant and benign pulmonary lesions with relatively high accuracy \[7, 16\]. The purpose of our study is to determine whether DCE MRI analysis of tumor angiogenesis and perfusion can be used as a reliable modality to differentiate benign from malignant SPN before surgical intervention, using kinetic model derived from DCE MRI, and further correlate if there is any positive correlation between angiogenesis factor (vascular endothelial growth factor VEGF, microvessel density MVD); and if the perfusion parameters from DCE MRI can predict patients' outcomes and survival.
The diagnosis of GDM is based on a 75-g oral glucose tolerance test (OGTT) performed between 24 and 28 gestational weeks, according to the American diabetes association (ADA) criteria (fasting ≥ 5.1 mmol/L, 1 h ≥ 10.0 mmol/L, 2 h ≥ 8.5 mmol/L). Recruited patients were accepted the standard of treatment of GDM according to the American college of obstetricians and gynecologists (ACOG) practice bulletin on gestational diabetes mellitus.
PURPOSE:To provide a stable cosmetic having antiphlogistic and tissue regenerating activities, by extracting TOKI (root of Angelica acutiloba) with a mixture of water and an organic solvent such as ethyl alcohol, storing the extract at a low temperature or a high temperature, removing the precipitated solid component from the liquid, and using the resultant TOKI extract as an active component. CONSTITUTION:TOKI is extracted with a mixture of water and an organic solvent miscible with water and capable of extracting oil-soluble components, e.g. ethyl alcohol, isopropyl alcohol, ethylene glycol, glycerol, etc. and the obtained crude extract is stored at a low temperature to promote the formation of sediments by the decrease of the solubility or stored at a high temperature to promote the formation of sediments by ripening effect. The precipitated solid component is removed from the liquid, and the obtained TOKI extract liquid is used as a component of the objective cosmetic. The weight ratio of water to the organic solvent used as the extractant is preferably (90:55):(10:45), especially (80- 60):(20-40).
To lower the risk of constipation, LOTRONEX should be started at a dosage of 0.5 mg twice a day. Patients who become constipated at this dosage should stop taking LOTRONEX until the constipation resolves. They may be restarted at 0.5 mg once a day. If constipation recurs at the lower dose, LOTRONEX should be discontinued immediately. 

Patients well controlled on 0.5 mg once or twice a day may be maintained on this regimen. If after 4 weeks the dosage is well tolerated but does not adequately control IBS symptoms, then the dosage can be increased to up to 1 mg twice a day. LOTRONEX should be discontinued in patients who have not had adequate control of IBS symptoms after 4 weeks of treatment with 1 mg twice a day.

LOTRONEX can be taken with or without food [see Clinical Pharmacology (12.3)]. 

LOTRONEX should be discontinued immediately in patients who develop constipation or signs of ischemic colitis. LOTRONEX should not be restarted in patients who develop ischemic colitis. 

Clinical trial and postmarketing experience suggest that debilitated patients or patients taking additional medications that decrease gastrointestinal motility may be at greater risk of serious complications of constipation. Therefore, appropriate caution and follow-up should be exercised if LOTRONEX is prescribed for these patients. 

Postmarketing experience suggests that elderly patients may be at greater risk for complications of constipation; therefore, appropriate caution and follow-up should be exercised if LOTRONEX is prescribed for these patients [see Warnings and Precautions (5.1)].
The present invention relates to novel liver related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as “liver antigens,” and the use of such liver antigens for detecting disorders of the liver, particularly the presence of cancer of liver and cancer metastases. More specifically, isolated liver associated nucleic acid molecules are provided encoding novel liver associated polypeptides. Novel liver polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human liver associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the liver, including cancer of liver tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.
The comorbidity between cocaine use disorder (CUD) and trauma/stressor-related disorders suggests a connection between neurophysiological changes induced by stress and those that lead to cocaine use. Due to the unexpected and sometimes uncontrollable nature and timing of stressful life events, their capacity to induce drug use poses a significant challenge for the administration of cocaine relapse therapy. This study aims to investigate the impact of chronic stress applied prior to cocaine acquisition on the development of cocaine-seeking behavior after different periods of drug abstinence in male and female rats. Rats were exposed to five days of inescapable footshocks (chronic stress) before undergoing extended access cocaine self-administration. Different groups then underwent forced abstinence periods of 1, 15, or 30 days before cue- and cocaine-induced seeking tests. Results showed that, after 30 days of abstinence, stressed females exhibited higher cue-induced, but not cocaine-induced seeking, compared to female controls and to males. In contrast, at 30 days, stressed males showed higher cocaine-, but not cue-induced seeking, versus controls. Such sex-dependent alterations in motivation and drug effects following prolonged abstinence highlight the importance of considering sex-specific differences in stress-related addiction research. Ongoing work should evaluate other stressors and self-administration models to elucidate neurophysiological and hormonal mechanisms underlying the incubation of cocaine craving. Identifying shared pathways between chronic stress and addiction could offer novel strategies for treating trauma/stress-related substance use disorders in a sex-specific manner.
The current disclosure, in one embodiment, includes a polysaccharide conjugate. This conjugate has a polysaccharide and at least one monomeric amino acid having an O-group covalently bound to the polysaccharide. The conjugate also has at least one metal conjugated by the O-group of the amino acid. According to another embodiment, the disclosure provides a method of synthesizing a polysaccharide conjugate by covalently bonding a monomeric amino acid having an O-group to a polysaccharide and by conjugating a metal to the O-group to form a polysaccharide conjugate. According to a third embodiment, the disclosure relates to a method of killing a cancer cell by administering to the cell an effective amount of a polysaccharide conjugate. This conjugate has a polysaccharide and at least one monomeric amino acid having an O-group covalently bound to the polysaccharide. The conjugate also has at least one metal conjugated by the O-group of the amino acid.
An anti-CD47 monoclonal antibody and use thereof. The provided anti-CD47 monoclonal antibody can effectively inhibit tumor growth. Blocking human SIRP and human CD47 signals may enhance macrophage phagocytosis of tumor cells, prevent the tumor cells from escaping a tumor immune defense system, and have an anti-tumor function. Blocking association between the CD47 on a tumor cell surface and the SIRP on a macrophage surface may block a "do not eat me" signal from the tumor cells, promoting tumor cell recognition and uptake of macrophages, and thereby facilitating tumor cells to be phagocytosed. The association between the CD47 on a tumor cell surface and the SIRP on a macrophage surface is a common "do not eat me" signal. The anti-CD47 antibody, as a very promising target in the tumor immune system, will play a powerful and effective role in human cancer therapy.
The application discloses a medical disinfection ultrasonic coupling agent and a preparation method thereof, belonging to the technical field of disinfection. The medical disinfection ultrasonic coupling agent comprises the following components in percentage by weight: 0.5 to 5 percent of thickening agent, 0.01 to 1 percent of disinfectant, 1.0 to 5.0 percent of stabilizer, 0.5 to 3.0 percent of moisturizing and skin-care agent, 0.5 to 3.0 percent of lubricant, 0.5 to 5 percent of neutralizer and the balance of water. The medical disinfection ultrasonic coupling agent is prepared by sequentially adding a thickening agent, a disinfectant, a stabilizer, a moisturizing skin care agent, a lubricant and a neutralizing agent into water and uniformly stirring. The medical disinfection ultrasonic coupling agent can achieve the disinfection effect in a short time, has good stability of the disinfection effect, does not generate yellowing, and is convenient to operate and clear in imaging. The couplant has no toxicity and no irritation to skin. The preparation process is simple and is easy for industrial production.